Yazar "Celikkol, Aliye" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Creatine Kinase (CK)-MB and CK-MB-to-Total-CK Ratio: A Novel Predictive Marker for Pathologic Complete Response in Breast Cancer Treated with Neoadjuvant Chemotherapy(Akad Doktorlar Yayinevi, 2024) Cavdar, Eyyup; Karaboyun, Kubilay; Iriagac, Yakup; Celikkol, Aliye; Elcicek, Omer; Avci, Okan; Seber, ErdoganBreast cancer is the most common cancer and neoadjuvant chemotherapy(NAC) is one of the important treatment modalities in early stage breast cancer. The aim of this study was to investi-gate the ability of serum CK-MB and CK-MB/CK to be an ideal predictive marker for pathologic complete response (pCR) in breast cancer patients receiving NAC and to determine its rela-tionship with clinicopathologic factors. A total of 135 breast cancer patients receiving NAC were included in this retrospective study. The pre-NAC serum laboratory values and clinicopathologi-cal features of the patients were recorded. Regression analysis was used to do predictive factor analysis for pCR. In the statistical analysis, serum CK-MB level was associated with axillary status, PgR status, ER status, and HER2 status. A significant relationship between CK-MB/CK and axillary status and histological grade was found. PgR negativity, ER negativity, high histo-logical grade, axillary negativity, NLR, CK-MB elevation, and high CK-MB/CK ratio were found to be predictive factors for pCR in the univariate regression analysis.CK-MB (OR= 3.48, p= 0.032) and CK-MB/CK ratio (OR= 3.16, p= 0.028) were revealed to be strong predictors of pCR in established multivariate models.In survival analysis, recurrence-free survival (RFS) were shorter in patients with low CK-MB/CK ratio (p= 0.045). There was no significant relationship between CK-MB level and RFS (p= 0.315). In summary, in breast cancer patients who have re-ceived NAC, serum CK-MB level and CK-MB/CK ratio are independent predictors of pCR.To the best of our knowledge, this study is the first to assess these variables' predictive impact on NAC response in breast cancer patients.Öğe Effects of Tranexamic Acid on Acute Lung Injury in Rats Exposed to Aortic Ischemia-Reperfusion(Wiley, 2023) Ozcan, Betul; Deger, Ecem Busra; Mengi, Murat; Oznur, Meltem; Celikkol, Aliye; Topcu, Birol; Guner, Ibrahim[Abstract Not Available]Öğe Predictive Value of Serum Calprotectin Level in Response to Treatment, a New Inflammatory Marker in Patients with Breast Cancer Requesting Neoadjuvant Treatment(Galenos Publ House, 2023) Baydar, Ece; Celikkol, Aliye; Gurdal, Sibel Ozkan; Seber, SelcukAim: There is a close relationship between inflammation and cancer. Calprotectin is a protein released during inflammation. The aim of this study is to investigate the relationship between breast cancer and calprotectin levels in breast cancer patients receiving neoadjuvant therapy the predictive role of calprotectin in response to treatment. Materials and Methods: In our prospective study, a patient group with 69 breast cancer patients and a control group with 20 patients were formed. Calprotectin was studied from the blood tests taken from the whole sample. Patient data were obtained from the electronic record system. In our study, statistical evaluations were made using a package program called IBM Statistical Package for the Social Sciences Statistics 24. Results: Eighty-nine patients (69 cancer, 20 controls) were included in the study. The median age of breast cancer patients was 48 [minimum (min): 24-maximum (max): 73], the control group was 44.5 (min: 19-max: 68) and the ages of the two groups were similar (p=0.599). Mean calprotectin levels in breast cancer patients were 28.63 +/- 30.5, median 16.5 (min: 6.7-max: 160.7). The mean in the control group was 16.09 +/- 6.1 (min: 8.7-max: 27.4) and there was no statistical difference between the 2 groups (p=0.072). A statistically significant difference was found in terms of calprotectin values according to Ki67 classes (Z=-20.043; p=0.041). Calprotectin values of those with Ki67 class >20 were statistically significantly higher than those with <= 20. Parameters that could predict complete chemotherapy response were evaluated with logistic regression analysis. There was no correlation between calprotectin level and complete response. There was a positive correlation between age increase and complete response. Conclusion: There was no significant difference between serum calprotectin levels of the patient and control groups, but calprotectin level was found to be associated with Ki67 level. There was no relationship between calprotectin and chemotherapy response. Studies with larger sample numbers may make a significant difference.Öğe Serum chromogranin A levels are associated with the SYNTAX score in coronary artery disease(Assoc Medica Brasileira, 2023) Celikkol, Aliye; Demirkiran, Aykut; Aydin, Cihan; Akyuz, Aydin; Kaplangoray, Mustafa; Yilmaz, Ahsen; Efe, Muhammed MucipOBJECTIVE: In this article, we investigated the association of chromogranin A with coronary artery disease.METHODS: Biochemical parameters and chromogranin A levels obtained from peripheral blood samples during coronary angiography were analyzed in 90 patients. Patients were classified into two groups, namely, SYNergy between PCI with TAXUS and Cardiac Surgery score >= 1 (n=45) and SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (n=45). This is a cross-sectional, prospective study. RESULTS: Serum chromogranin A levels were significantly higher in the group with SYNergy between PCI with TAXUS and Cardiac Surgery score >= 1 compared to the group with SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (1381.5 +/- 418.9 ng/mL and 1121.2 +/- 290.7 ng/mL, respectively; p=0.002). Serum chromogranin A levels were correlated with SYNergy between PCI with TAXUS and Cardiac Surgery score (r=0.556, p<0.04). ROC analysis showed that the area under the curve for serum chromogranin A levels was 0.687 (p=0.007), and the best cutoff value of 1,131 ng/mL had a sensitivity of 67% and a specificity of 65% for the prediction of coronary artery disease.CONCLUSION: Serum chromogranin A levels were increased in coronary artery disease patients with SYNergy between PCI with TAXUS and Cardiac Surgery score >= 1. Increasing serum chromogranin A levels are proportional to the SYNergy between PCI with TAXUS and Cardiac Surgery score.KEYWORDS: Chromogranin A. Coronary artery disease. Hypertension.Öğe Serum Soluble Urokinase Plasminogen Activator Receptor Levels in Resistant Hypertension(Aves, 2024) Bayrakci, Nergiz; Ozkan, Gulsum; Kara, Sonat Pinar; Yilmaz, Ahsen; Celikkol, AliyeBackground: Although the precise pathogenetic mechanisms remain incompletely elucidated, hypertension is characterized by endothelial damage and inflammation. The soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker that increases in parallel with disease activity in conditions such as systemic inflammation, infection, cancer, and atherosclerosis. The objective of this study was to assess inflammation by means of serum suPAR levels in hypertensive patients and those with resistant hypertension. Methods: Eighty-six adults, 29 newly diagnosed hypertensive patients (HT group) and 23 resistant hypertensive patients (RHT group) and 34 healthy controls, were included in this cross-sectional, observational study. Ambulatory blood pressure monitoring results were included in the analysis. Serum suPAR levels were measured using Enzyme -Linked ImmonuSorbent Assay (ELISA). Patients were divided into 2 groups as high suPAR and low suPAR. Results: The serum suPAR level was lower in the control group than that of the HT and RHT groups (P = .001). Systolic and diastolic blood pressure values were positively correlated with the serum suPAR level (r = 0.254, P = .018; r = 0.239, P = .027, respectively). Being in the high-suPAR group was found to increase the risk of RHT by 19.5 times. Other risk factors for RHT were found to be lower urinary sodium excretion and higher urinary albumin excretion [odds ratio (OR) = 0.98; OR = 1.09, respectively]. Conclusion: In our study, suPAR levels were found associated with RHT. To our best knowledge, this study is the first to evaluate the relationship between serum suPAR levels and RHT.Öğe The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats(Pergamon-Elsevier Science Ltd, 2023) Uslu, Esra Toplu; Mengi, Murat; Beyazyuz, Elmas; Celikkol, Aliye; Albayrak, YakupTardive dyskinesia (TD) is a persistent involuntary complex movement disorder that is known to occur with long-term antipsychotic treatment. Despite being a well-recognized complication of this treatment, its symptoms are often masked by the antipsychotic agents, only to become apparent upon reducing or terminating the treatment. In an effort to advance our understanding of TD pathophysiology and to identify potential therapies, the current study aimed to establish an animal model of TD by administering haloperidol to rats and to evaluate the efficacy of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), in ameliorating TD symptoms. The study compared the behavioral and biochemical parameters of rats that were treated with either fluvoxamine, tetra-benazine, haloperidol, or saline (control group). The biochemical parameters of interest included the brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), and malondial-dehyde (MDA). To achieve the study objectives, 32 male Wistar Albino rats were assigned to four different groups. The control group received physiological saline for six weeks. The haloperidol group received 1 mg/kg/ ip haloperidol for the first three weeks, followed by two weeks of saline. The haloperidol+fluvoxamine group received 1 mg/kg/ip haloperidol for the first three weeks, followed by 30 mg/kg/ip fluvoxamine. The hal-operidol+tetrabenazine group was administered 1 mg/kg/ip haloperidol for the first three weeks, followed by 5 mg/kg/ip tetrabenazine. Behavioral assessments of the rats were performed by measuring vacuous chewing movements. Subsequently, samples were collected from the hippocampus, striatum, and frontal lobe tissues of the rats, and BDNF, NGF, SOD, and MDA levels were measured. The results of the study demonstrated significant differences between the groups with respect to behavioral observations. Furthermore, SOD levels in the hip-pocampus, as well as BDNF, NGF, and SOD levels in the striatum of the haloperidol+fluvoxamine group were significantly higher than those observed in the haloperidol group. Conversely, MDA levels in the hippocampus were significantly lower in the haloperidol+fluvoxamine group than in the haloperidol group. These findings provide evidence of the beneficial effects of fluvoxamine, acting as a sigma-1 agonist, in treating TD symptoms induced experimentally. The observed benefits were supported by the biochemical investigations performed on brain tissue samples. Therefore, fluvoxamine may be considered as a potential alternative treatment for TD in clinical practice, although further research is needed to corroborate these findings.Öğe The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy(Galenos Publ House, 2023) Karaboyun, Kubilay; Cavdar, Eyyup; Iriagac, Yakup; Yilmaz, Ahsen; Celikkol, Aliye; Avci, Okan; Seber, Erdogan SelcukIntroduction: This study investigated the relationship between serum interleukin-20 (IL-20) levels and paclitaxel-associated neuropathy in patients with non-metastatic breast cancer. Paclitaxel-induced peripheral neuropathy (PIPN) is a significant side effect of paclitaxel chemotherapy, and the exact mechanism underlying PIPN is not fully understood. Methods: This prospective observational study was conducted with non-metastatic breast cancer patients between January 2022 and November 2022. Neuropathy symptoms were evaluated using the QLQ-CIPN20 questionnaire, and serum IL-20 levels were measured at three time points: before chemotherapy, on the 7(th) day after the first paclitaxel treatment, and after the last treatment. Univariate and multivariate logistic regression analyses were performed to identify factors predicting PIPN. Results: This study was completed with 59 female patients. During the study, 47 patients (79.6%) reported any degree of neuropathy, whereas 12 patients (20.4%) had no neuropathy. Univariate analysis to predict neuropathy measured on day 7 after first paclitaxel administration demonstrated that age, body mass index, 7(th)-day serum IL-20 level, and last cycle serum IL-20 level were predictive for PIPN. Conclusion: This study demonstrated the relationship between serum IL-20 levels and paclitaxel-related neuropathy in breast cancer patients. Further research targeting the function of IL-20 is needed to investigate potential strategies to prevent and treat PIPN.
